Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal
pharmaphorum
JULY 5, 2021
The new deal will assists the company’s focus “on advancing and innovating Parexel to meet our customers’ needs across the evolving clinical development landscape,” he added. ” The deal is subject to the usual conditions, including receipt of various approvals from regulators around the world.
62 
Let's personalize your content